The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without the manual effort and uncertainty of traditional methods. The area of each Optofluidic chip NanoPen™ chamber is ~700 times smaller than that of a microwell, leaving nowhere for “ghost cells” to hide.
Kim, L et al., Amgen. Read paper.
Download the application note on: FDA-Accepted Monoclonality Assurance on The Beacon® Optofluidic System for Cell Line Development to learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.